DiaMedica Therapeutics Inc. (DMAC)

Several events have impacted DiaMedica Therapeutics, Inc.'s stock price in the past six months. A regulatory delay occurred when the FDA requested an additional non-clinical study for DM199 in preeclampsia. DiaMedica completed a block trade, selling 1,501,000 common shares at $8.10 per share. The company has reported persistent financial losses and negative earnings per share (EPS) forecasts. DiaMedica Therapeutics received a "No Objection Letter" from Health Canada to initiate a Phase 2 study of DM199 in early-onset preeclampsia. The ReMEDy2 Phase 2/3 acute ischemic stroke trial of DM199 is approaching 70% of the required enrollment for its planned interim analysis. Between March 27, 2025, and March 26, 2026, DiaMedica Therapeutics Inc. (DMAC) saw its share price increase by 65.46%.

DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies, and its products and services do not exhibit traditional demand seasonality. Demand for its product candidates, if approved, would be driven by medical need and regulatory approvals rather than seasonal fluctuations.

DiaMedica Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for vascular diseases and central nervous system conditions, operating within the Medical and Health Technology sectors. The company specializes in creating synthetic proteins, with its lead product candidate being DM199 (rinvecalinase alfa), a recombinant form of human tissue kallikrein-1 (rhKLK1). DM199 is being evaluated in clinical trials for acute ischemic stroke (AIS), preeclampsia (PE), and fetal growth restriction (FGR). Another product candidate in DiaMedica's pipeline is DM300, a patented recombinant human ulinastatin, which is in the pre-clinical stage for the treatment of inflammatory diseases.

DiaMedica Therapeutics, Inc.'s operational office is located in Minneapolis, Minnesota, United States, and the company primarily operates in the United States and Canada.

DiaMedica Therapeutics' brand reputation has been influenced by clinical development progress and financial standing. Discussions have highlighted insider buying and upcoming presentations as strong signals of confidence. However, there has also been caution, including a recent downgrade by a research firm to a 'sell' rating. Analyst ratings for DMAC show a consensus of "Moderate Buy" from six brokerages. Potential adverse events associated with DM199 could pose safety concerns that might hinder patient acceptance and regulatory approval.

DiaMedica Therapeutics Inc. has 96 institutional owners and shareholders holding a total of 11,283,000 shares. The ownership structure of DMAC stock is a mix of institutional, insider, and retail investors. Approximately 23.15% is held by institutional shareholders, 71.44% by DiaMedica Therapeutics insiders, and 5.42% by retail investors. Jan Stahlberg is identified as the largest individual DiaMedica Therapeutics shareholder, owning 15.59 million shares, representing 29.94% of the company.